U.S. Capital Wealth Advisors, LLC Alnylam Pharmaceuticals, Inc. Transaction History
U.S. Capital Wealth Advisors, LLC
- $3.21 Billion
- Q2 2025
A detailed history of U.S. Capital Wealth Advisors, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, U.S. Capital Wealth Advisors, LLC holds 52,027 shares of ALNY stock, worth $22.4 Million. This represents 0.53% of its overall portfolio holdings.
Number of Shares
52,027
Previous 56,011
7.11%
Holding current value
$22.4 Million
Previous $15.1 Million
12.17%
% of portfolio
0.53%
Previous 0.49%
Shares
4 transactions
Others Institutions Holding ALNY
# of Institutions
745Shares Held
111MCall Options Held
916KPut Options Held
841K-
Capital World Investors Los Angeles, CA16.8MShares$7.22 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$5.72 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.1 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.09 Billion0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.9 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $52.9B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...